PRESS RELEASE published on 01/30/2025 at 18:00, 10 months 5 days ago THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT Theranexus announces cash position of €4.0 M as of 29 January 2025, strengthening financial outlook. Biopharmaceutical company progressing on rare neurological disease treatments, including Niemann-Pick and Gaucher diseases Cash Position Biopharmaceutical Financial Outlook Theranexus Neurological Diseases
BRIEF published on 01/23/2025 at 18:20, 10 months 12 days ago Theranexus Unveils 2025 Financial Calendar Financial Calendar Biopharmaceutical Theranexus Neurological Diseases 2025 Schedule
PRESS RELEASE published on 01/23/2025 at 18:15, 10 months 12 days ago THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025 Theranexus, a biopharmaceutical company in rare neurological disease treatment, announces its 2025 financial communication agenda for Euronext market. Dates subject to change Euronext Biopharmaceutical Financial Communication Theranexus Neurological Diseases
BRIEF published on 01/23/2025 at 18:05, 10 months 12 days ago Theranexus Announces its Financial Agenda for 2025 Euronext Paris Financial Agenda Theranexus Financial Publications Neurological Diseases
BRIEF published on 01/16/2025 at 18:05, 10 months 19 days ago Theranexus: Monthly update of voting rights and shares Voting Rights Actions Stock Market Biopharmaceutical Theranexus
BRIEF published on 01/09/2025 at 18:05, 10 months 26 days ago Theranexus Publishes its Letter to Shareholders Financial Outlook Theranexus Rare Neurological Diseases Letter To Shareholders Innovative Platform
PRESS RELEASE published on 01/09/2025 at 18:00, 10 months 26 days ago THERANEXUS ANNOUNCES THE PUBLICATION OF ITS LETTER TO SHAREHOLDERS Theranexus, an innovative biopharmaceutical company, announces the publication of its letter to shareholders. Shareholders can download the newsletter from the company website Shareholders Biopharmaceutical Newsletter Theranexus Neurological Diseases
BRIEF published on 12/17/2024 at 18:20, 11 months 18 days ago Theranexus optimizes its cash flow and extends its financial horizon Treasury Funding License Agreement Theranexus Batten Disease
PRESS RELEASE published on 12/17/2024 at 18:15, 11 months 18 days ago THERANEXUS PRESENTS AN UPDATE OF ITS CASH POSITION AND FINANCING HORIZON Theranexus presents an update of its cash position and cash flow horizon, expecting improvement through upcoming payments and restructuring agreement with banking partners Cash Position Cash Flow Financial Debt Theranexus Banking Partners
BRIEF published on 12/17/2024 at 18:05, 11 months 18 days ago License agreement between Theranexus and Exeltis for TX01 Rare Diseases License Agreement Theranexus Exeltis TX01
Published on 12/05/2025 at 02:35, 9 hours 25 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 11 hours ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 55 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:30, 1 hour 30 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 45 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 19 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 2 hours 30 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 08:45, 3 hours 15 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 18 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 18 hours 15 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 18 hours 16 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
